Farangis Yazdanjou

Farangis Yazdanjou

Auto-generated profile, based on publicly available information

Farangis Yazdanjou

Department of Ophthalmology, Imam Hossein Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2024 in Journal of Renal Injury Prevention
Verified
Journal Article
Open access
PDF file
SBShahriar Barkhordari
Shahriar Barkhordari
RARoya Azouji
Roya Azouji
FYFarangis Yazdanjou
Farangis Yazdanjou
ANArash Neshati
Arash Neshati
AAAmirhosein Abareghi
Amirhosein Abareghi
JRJalal Rezaei
Jalal Rezaei
Introduction: Sjogren’s syndrome is an autoimmune disorder with variable prevalence in different parts of the world. This study aims to estimate the prevalence of Sjogren’s syndrome worldwide using a systematic review and meta-analysis. Materials and Methods: For this study, we searched the databases of PubMed, ProQuest, Cochrane, Web of Science, and the Google Scholar search engine without any time limit until February 17, 2024. We used STATA 14 software for data analysis, and the significance level was set at P<0.05. Results: Combining the findings of 24 observational studies with a total of 211349 participants, we concluded that the overall prevalence of Sjogren’s syndrome in the world and the female population was (13%; [95% CI: 10%, 16%]) and (15% [95% CI: 4%, 26%]), respectively. The worldwide prevalence of Sjogren’s syndrome in cohort studies and cross-sectional studies was (14% [95% CI: 10%, 19%]) and (10% [95% CI: 7%, 14%]), respectively. However, the prevalence of primary Sjogren’s syndrome was (7% [95% CI: 5%, 9%]) and the prevalence of secondary Sjogren syndrome was (9% [95% CI: 6%, 13%]). Additionally, the prevalence of Sjogren’s syndrome among the age groups of 20-29, 30-39, 40-49, 50-59, 60-69, and 70-79 years was (31% [95% CI: 30%, 42%]), (4% [95% CI: 1%, 6%]), (7% [95% CI: 5%, 10%]), (24% [95% CI: 15%, 33%]), (22% [95% CI: 2%, 42%]), and (5% [95% CI: 1%, 9%]), respectively. Conclusion: Sjogren’s syndrome has a high overall prevalence in the world, and considering the adverse outcomes of this disease, there should be measures taken to control and screen the prevalence of Sjogren’s disease. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42024513783) and Research Registry (UIN: reviewregistry1793) website.

29 June 2024 in Journal of Nephropharmacology
Verified
Journal Article
Closed access
SBShahriar Barkhordari
Shahriar Barkhordari
SGShahrzad Ghaffariyan
Shahrzad Ghaffariyan
FBFarzin Banei
Farzin Banei
MSMohammad Shirvani
Mohammad Shirvani
FYFarangis Yazdanjou
Farangis Yazdanjou
MMMobin Mohammadtabar
Mobin Mohammadtabar
Introduction: Diabetic retinopathy is one of the principal causes of blindness globally. The impact of sodium-glucose cotransporter 2 (SGLT-2) inhibitors, a category of anti-diabetic medications, on diabetic retinopathy remains undetermined. Consequently, this study aimed to examine the association between the utilization of SGLT2 inhibitors and the incidence of diabetic retinopathy. Materials and Methods: This investigation systematically searched databases, including Web of Science, Cochrane, ProQuest, PubMed, and Google Scholar, until March 7, 2024. A systematic review and meta-analysis methodology was employed. Data were analyzed using STATA software version 14, considering a significance level of tests at P<0.05. Results: The application of SGLT2 inhibitors was connected with a diminished diabetic retinopathy risk (odds ratio [OR]: 0.77, 95% CI: 0.69, 0.86). Among women, SGLT2 inhibitor use did not notably influence diabetic retinopathy risk (OR: 0.84, 95% CI: 0.69, 1.03). However, among men, employing SGLT2 inhibitors decreased the risk (OR: 0.81, 95% CI: 0.71, 0.92). In comparison to dipeptidyl peptidase-4 inhibitors (OR: 0.70, 95% CI: 0.53, 0.94) and pioglitazone (OR: 0.75, 95% CI: 0.74, 0.76), SGLT2 inhibitors lowered the risk of diabetic retinopathy. However, when compared to sulfonylureas (OR: 0.45, 95% CI: 0.17, 1.17) and GLP1-RA (OR: 0.70, 95% CI: 0.42, 1.17), SGLT2 inhibitors did not notably affect diabetic retinopathy. Moreover, using SGLT2 inhibitors in the age groups of 50-54 years (OR: 0.74, 95% CI: 0.55, 0.98), 55-59 years (OR: 0.65, 95% CI: 0.53, 0.79), and 60-64 years (OR: 0.89, 95% CI: 0.82, 0.97) was linked to lower diabetic retinopathy risk. Nevertheless, in the 65-69 age group, SGLT2 inhibitor administration did not significantly alter the diabetic retinopathy risk (OR: 1.04, 95% CI: 0.94, 1.15). Conclusion: The intake of SGLT2 inhibitors has been linked to a diminution in the hazard of diabetic retinopathy. However, further research in this domain is recommended, given the need for studies examined. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42024523959) and Research Registry (UIN: reviewregistry1808) website.